Windsor Rachael, Strauss Sandra, Seddon Beatrice, Whelan Jeremy
The London Sarcoma Service, UCL Hospitals NHS Foundation Trust, First Floor Central, 250 Euston Road, NW1 2PG, London, UK.
Expert Opin Investig Drugs. 2009 Feb;18(2):143-59. doi: 10.1517/13543780802715784.
Ewing's sarcoma/primitive neuroectodermal tumours (ES/PNET) are aggressive musculoskeletal tumours with a predilection for young people. With current treatments, significant numbers of patients relapse and survival is poor for those with metastatic disease.
To review current experimental treatment strategies in ES/PNET and prospects for the future.
A review of the literature and recent meeting presentations on established and experimental cytotoxic and biological therapies in the treatment of ES/PNET was performed.
RESULTS/CONCLUSION: New combinations of conventional and emerging cytotoxics show some promise. Molecular techniques are being used to identify high-risk patients and potential cellular targets. Several novel biologically targeted agents have demonstrated encouraging preliminary clinical efficacy; it is hoped these combined with current chemotherapeutic agents may improve outcome in ES/PNET.
尤因肉瘤/原始神经外胚层肿瘤（ES/PNET）是侵袭性肌肉骨骼肿瘤，好发于年轻人。采用目前的治疗方法，大量患者会复发，而转移性疾病患者的生存率很低。
综述ES/PNET目前的实验性治疗策略及未来前景。
对已发表的文献以及近期会议上有关ES/PNET治疗中既定的和实验性细胞毒性及生物疗法的报告进行综述。
结果/结论：传统细胞毒性药物与新型细胞毒性药物的新组合显示出一定前景。分子技术正用于识别高危患者和潜在的细胞靶点。几种新型生物靶向药物已显示出令人鼓舞的初步临床疗效；希望这些药物与目前的化疗药物联合使用可改善ES/PNET的治疗效果。
